Genmab As Stock Today
| GMAB Stock | USD 20.53 0.08 0.39% |
Performance0 of 100
| Odds Of DistressLess than 1
|
Genmab AS is trading at 20.53 as of the 21st of November 2024, a 0.39 percent up since the beginning of the trading day. The stock's open price was 20.45. Genmab AS has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on August 15, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Genmab AS's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of June 2009 | Category Healthcare | Classification Health Care |
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States. The company has 635.14 M outstanding shares of which 2.34 M shares are currently shorted by private and institutional investors with about 1.84 trading days to cover. More on Genmab AS
Moving together with Genmab Stock
| 0.79 | VRAX | Virax Biolabs Group | PairCorr |
| 0.63 | VRPX | Virpax Pharmaceuticals | PairCorr |
| 0.68 | DYN | Dyne Therapeutics | PairCorr |
| 0.85 | XFOR | X4 Pharmaceuticals | PairCorr |
Moving against Genmab Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Genmab Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Tahamtan Ahmadi | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cash Cows (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, OMX Copenhagen All, OMX Copenhagen 20, OMX Copenhagen 25, Cash Cows, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGenmab AS can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Genmab AS's financial leverage. It provides some insight into what part of Genmab AS's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Genmab AS (GMAB) is traded on NASDAQ Exchange in USA. It is located in Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 and employs 2,635 people. Genmab AS is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 13.13 B. Genmab AS conducts business under Biotechnology sector and is part of Health Care industry. The entity has 635.14 M outstanding shares of which 2.34 M shares are currently shorted by private and institutional investors with about 1.84 trading days to cover.
Genmab AS currently holds about 21.61 B in cash with 7.38 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 33.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Genmab AS Probability Of Bankruptcy
Ownership AllocationGenmab AS has a total of 635.14 Million outstanding shares. Roughly 91.59 (percent) of Genmab AS outstanding shares are held by general public with 0.007 % owned by insiders and only 8.4 pct. by outside corporations. On August 15, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Genmab AS's common stock.
Check Genmab Ownership Details
Genmab Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-06-30 | 877.9 K | |
| Royal Bank Of Canada | 2024-06-30 | 792.8 K | |
| Wells Fargo & Co | 2024-06-30 | 723.5 K | |
| Two Sigma Investments Llc | 2024-06-30 | 709.6 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 648.4 K | |
| Ddd Partners, Llc | 2024-09-30 | 583.1 K | |
| Voloridge Investment Management, Llc | 2024-06-30 | 528.2 K | |
| Northern Trust Corp | 2024-09-30 | 504.5 K | |
| American Century Companies Inc | 2024-09-30 | 397.1 K | |
| Alliancebernstein L.p. | 2024-06-30 | 15.2 M | |
| Blackrock Inc | 2024-06-30 | 5.1 M |
Genmab AS Historical Income Statement
Genmab Stock Against Markets
Genmab AS Corporate Executives
Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony CPA | Executive CFO | Profile | |
| Anthony Mancini | Executive COO | Profile | |
| Rayne Waller | Executive CTO | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.38) | Earnings Share 1.02 | Revenue Per Share 30.6997 | Quarterly Revenue Growth 0.176 | Return On Assets 0.1095 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.